Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial.
Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial.
复制标题
DOI：
10.1093/infdis/jiad023
复制
发表时间：
2023-05-29
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) reduces hospitalizations among outpatients treated early after symptom onset. It is unknown whether CCP reduces time to symptom resolution among outpatients. We evaluated symptom resolution at day 14 by trial arm using an adjusted subdistribution hazard model, with hospitalization as a competing risk. We also assessed the prevalence of symptom clusters at day 14 between treatments. Clusters were defined based on biologic clustering, impact on ability to work, and an algorithm. Among 1070 outpatients followed up after transfusion, 381 of 538 (70.8%) receiving CCP and 381 of 532 (71.6%) receiving control plasma were still symptomatic (P = .78) at day 14. Associations between CCP and symptom resolution by day 14 did not differ significantly from those in controls after adjustment for baseline characteristics (adjusted subdistribution hazard ratio, 0.99; P = .62). The most common cluster consisted of cough, fatigue, shortness of breath, and headache and was found in 308 (57.2%) and 325 (61.1%) of CCP and control plasma recipients, respectively (P = .16). In this trial of outpatients with early COVID-19, CCP was not associated with faster resolution of symptoms compared with control. Overall, there were no differences by treatment in the prevalence of each symptom or symptom clusters at day 14. NCT04373460. Early treatment with coronavirus disease 2019 convalescent plasma was not associated with faster symptom resolution than control treatment, in contrast with decreased hospitalization in the same population, suggesting that the timing antibody treatment may affect hospitalization and symptom progression differently.
登录
查看更多内容
DOI：
10.1056/nejmoa2102685
发表时间：
2021-10-07
期刊：
The New England journal of medicine
影响因子：
--
作者：
Dougan M;Nirula A;Azizad M;Mocherla B;Gottlieb RL;Chen P;Hebert C;Perry R;Boscia J;Heller B;Morris J;Crystal C;Igbinadolor A;Huhn G;Cardona J;Shawa I;Kumar P;Adams AC;Van Naarden J;Custer KL;Durante M;Oakley G;Schade AE;Holzer TR;Ebert PJ;Higgs RE;Kallewaard NL;Sabo J;Patel DR;Dabora MC;Klekotka P;Shen L;Skovronsky DM;BLAZE-1 Investigators
通讯作者：
BLAZE-1 Investigators
影响因子：
13.8
作者：
Bellan M;Soddu D;Balbo PE;Baricich A;Zeppegno P;Avanzi GC;Baldon G;Bartolomei G;Battaglia M;Battistini S;Binda V;Borg M;Cantaluppi V;Castello LM;Clivati E;Cisari C;Costanzo M;Croce A;Cuneo D;De Benedittis C;De Vecchi S;Feggi A;Gai M;Gambaro E;Gattoni E;Gramaglia C;Grisafi L;Guerriero C;Hayden E;Jona A;Invernizzi M;Lorenzini L;Loreti L;Martelli M;Marzullo P;Matino E;Panero A;Parachini E;Patrucco F;Patti G;Pirovano A;Prosperini P;Quaglino R;Rigamonti C;Sainaghi PP;Vecchi C;Zecca E;Pirisi M
通讯作者：
Pirisi M
DOI：
10.1056/nejmoa2103784
发表时间：
2021-11-18
期刊：
The New England journal of medicine
影响因子：
--
作者：
Korley FK;Durkalski-Mauldin V;Yeatts SD;Schulman K;Davenport RD;Dumont LJ;El Kassar N;Foster LD;Hah JM;Jaiswal S;Kaplan A;Lowell E;McDyer JF;Quinn J;Triulzi DJ;Van Huysen C;Stevenson VLW;Yadav K;Jones CW;Kea B;Burnett A;Reynolds JC;Greineder CF;Haas NL;Beiser DG;Silbergleit R;Barsan W;Callaway CW;SIREN-C3PO Investigators
通讯作者：
SIREN-C3PO Investigators
影响因子：
82.9
作者：
Blomberg B;Mohn KG;Brokstad KA;Zhou F;Linchausen DW;Hansen BA;Lartey S;Onyango TB;Kuwelker K;Sævik M;Bartsch H;Tøndel C;Kittang BR;Bergen COVID-19 Research Group;Cox RJ;Langeland N
通讯作者：
Langeland N
DOI：
10.1016/j.cmi.2021.02.008
发表时间：
2021-02-16
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Klein H;Asseo K;Karni N;Benjamini Y;Nir-Paz R;Muszkat M;Israel S;Niv MY
通讯作者：
Niv MY